These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 20557463

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ, Hübben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, van 't Wout J, Severens JL.
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A, Martín I, García Vargas M, Del Castillo A, Díaz S, Sánchez C.
    Clin Drug Investig; 2007 Aug; 27(3):197-205. PubMed ID: 17305414
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
    Clemons KV, Schwartz JA, Stevens DA.
    Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
    [Abstract] [Full Text] [Related]

  • 7. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.
    Chabrol A, Cuzin L, Huguet F, Alvarez M, Verdeil X, Linas MD, Cassaing S, Giron J, Tetu L, Attal M, Récher C.
    Haematologica; 2010 Jun; 95(6):996-1003. PubMed ID: 20007135
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA, Chodakewitz JA, Severino ME, Saddier P, Berman RS, Ryan DM, Dinubile MJ, Patterson TF, Denning DW, Walsh TJ.
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY.
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [Abstract] [Full Text] [Related]

  • 12. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment.
    Ehrmann S, Bastides F, Gissot V, Mercier E, Magro P, Bailly E, Legras A.
    Intensive Care Med; 2005 May; 31(5):738-42. PubMed ID: 15782314
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
    Garbino J, Schnetzler G, Roberts C.
    Swiss Med Wkly; 2006 Sep 30; 136(39-40):624-30. PubMed ID: 17086508
    [Abstract] [Full Text] [Related]

  • 15. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.
    Karthaus M.
    Eur J Med Res; 2011 Apr 28; 16(4):145-52. PubMed ID: 21486728
    [Abstract] [Full Text] [Related]

  • 16. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R.
    Int J Antimicrob Agents; 2015 Mar 28; 45(3):283-8. PubMed ID: 25455847
    [Abstract] [Full Text] [Related]

  • 17. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
    Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A.
    Value Health; 2006 Mar 28; 9(1):12-23. PubMed ID: 16441520
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A, Korb V, Guillemain R, Caruba T, Boussaud V, Billaud E, Prognon P, Begué D, Sabatier B.
    J Clin Pharm Ther; 2010 Feb 28; 35(1):49-53. PubMed ID: 20175811
    [Abstract] [Full Text] [Related]

  • 19. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ.
    N Engl J Med; 2005 Jan 27; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract] [Full Text] [Related]

  • 20. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K.
    Mycoses; 2011 May 27; 54(3):234-42. PubMed ID: 19906090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.